1
|
Zenati N, Charles J, Templier I, Blaise S. [Digital ischaemia with fingertip ulcers during ipilimumab therapy]. Ann Dermatol Venereol 2019; 147:212-216. [PMID: 31864764 DOI: 10.1016/j.annder.2019.09.606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 04/17/2019] [Accepted: 09/05/2019] [Indexed: 11/18/2022]
Abstract
BACKGROUND Anti-cancer drugs have many adverse effects including vascular side effects. Herein we present the case of a patient presenting digital ischaemia with high imputability of ipilimumab. OBSERVATION A 47-year-old male patient was treated for popliteal melanoma, initially stage IIIA but which subsequently became metastatic (stage IV), and for which ipilimumab was given after the failure of two lines of chemotherapy. During the 4th course of ipilimumab, the patient developed autoimmune hepatitis. Ipilimumab was suspended. Three months later, he developed a drug-like neuropathy followed one month later by ulceration of the right index finger. Causes of embolic, autoimmune and occupational origin (thrombotic microangiopathy, thrombosed aneurysm) were rapidly ruled out. Although a paraneoplastic origin could not be formally excluded, drug-induced immune disorder remained the most plausible origin. DISCUSSION This is the first reported case of digital ulceration under ipilimumab.
Collapse
Affiliation(s)
- N Zenati
- Department of Vascular Medicine, Grenoble University Hospital, 38000 Grenoble, France
| | - J Charles
- Department of dermatology, Grenoble University Hospital, 38000 Grenoble, France
| | - I Templier
- Department of dermatology, Grenoble University Hospital, 38000 Grenoble, France
| | - S Blaise
- Department of Vascular Medicine, Grenoble University Hospital, 38000 Grenoble, France; UMR 1042-HP2, Inserm, University of Grenoble-Alpes, 38000 Grenoble, France.
| |
Collapse
|
2
|
You OH, Shin EA, Lee H, Kim JH, Sim DY, Kim JH, Kim Y, Khil JH, Baek NI, Kim SH. Apoptotic Effect of Astragalin in Melanoma Skin Cancers via Activation of Caspases and Inhibition of Sry-related HMg-Box Gene 10. Phytother Res 2017; 31:1614-1620. [PMID: 28809055 DOI: 10.1002/ptr.5895] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 07/18/2017] [Accepted: 07/24/2017] [Indexed: 01/04/2023]
Abstract
Though Astragalin (kaempferol-3-glucoside) contained in Paeonia lactiflora and other plants was known to have anti-oxidant, antiinflammatory, and anti-tumor activity, the anti-tumor mechanism of Astragalin has never been reported in melanomas until now. Thus, in the present study, the underlying apoptotic mechanism of Astragalin isolated from Aceriphyllum rossii was elucidated in A375P and SK-MEL-2 melanoma cells. Astragalin exerted cytotoxicity in A375P and SK-MEL-2 cells in a concentration-dependent manner. Also, Astragalin significantly increased the number of TdT-mediated dUTP nick end labeling positive cells and sub-G1 population as a feature of apoptosis in A375P and SK-MEL-2 cells compared with untreated control. Consistently, western blotting revealed that Astragalin activated caspase 9/3 and Bax, cleaved poly (ADP-ribose) polymerase, and attenuated the expression of cyclin D1, Mcl-1, and Sry-related HMg-Box gene 10 (SOX10) in A375P and SK-MEL-2 cells. Of note, ectopic expression of SOX10 reduced the apoptotic ability of Astragalin to inhibit proliferation, cleave poly (ADP-ribose) polymerase, and caspase 3 in A375P and SK-MEL-2 melanoma cells. Overall, our findings provide evidence that Astragalin induces apoptosis in A375P and SK-MEL-2 melanoma cells via activation of caspase9/3 and inhibition of SOX10 signaling. Copyright © 2017 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Ok Heui You
- Department of East West Medical Science, Graduate School of East West Medical Science, Kyung Hee University, Yongin, 446-701, Korea
| | - Eun Ah Shin
- Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
| | - Hyemin Lee
- Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
| | - Ju-Ha Kim
- Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
| | - Deok Yong Sim
- Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
| | - Jung Hyo Kim
- Chosun Nursing College, 375 Seosuk-dong, Dong-gu, Gwangju, 501-759, Korea
| | - Younghwan Kim
- Institute of Sports Science, Kyung Hee University, Yongin, 446-701, South Korea
| | - Jae-Ho Khil
- Institute of Sports Science, Kyung Hee University, Yongin, 446-701, South Korea
| | - Nam-In Baek
- Department of Oriental Medicine Biotechnology, Graduate School of Biotechnology, Kyung Hee University, Yongin, 446-701, Korea
| | - Sung-Hoon Kim
- Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
| |
Collapse
|
3
|
[Quinze questions importantes à se poser en oncologie en 2015]. Bull Cancer 2015; 102:S22-6. [PMID: 26118872 DOI: 10.1016/s0007-4551(15)31214-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 04/09/2015] [Indexed: 11/23/2022]
Abstract
Cancers can now be classified by multidimensional criteria including tumour site, histology, primary - "driver" - molecular alterations, secondary molecular alterations, characteristics of the immune stroma, and genetic profile of the patient. The development of tools for the characterisation of the cancers, as well as novel molecular and immune therapeutics are evolving at an unprecedented pace. In 2012, a list of future challenges was identified at the occasion of the European Organisation for Research and Treatment of Cancer (EORTC) 50(th) anniversary. Three years after, it is interesting to look back at the questions addressed then and to assess the progress of these questions. We propose here a novel set questions which have emerged from the recent publications in this area.
Collapse
|
4
|
Troussier I, Baglin AC, Marcy PY, Even C, Moya-Plana A, Krengli M, Thariat J. Mélanomes muqueux de la tête et du cou : état actuel des pratiques et controverses. Bull Cancer 2015; 102:559-67. [DOI: 10.1016/j.bulcan.2015.04.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 01/29/2015] [Accepted: 04/14/2015] [Indexed: 02/03/2023]
|